Didn't it start it's trials much later than everyone else?
Oh, that would be good news because that means Johnson & Johnson, which is a heavyweight like Pfizer when it comes to production.
Don't know the overall number yet, but the antibody generation results are very good.
It's an adenovirus vector like Oxford/AZ. Basically those types use a harmless virus humans haven't been exposed to that acts as a trojan horse to train our immune system to what we really want it to fight (the spike protein).
Shouldn't you be near the front of the line?I'll take all the good news I can get. I'm a first responder, and still having a really hard time getting a vaccine.
What's storage like with this one? Is it easier to manage than the others?
I believe this one is considered a gamechanger because it is much easier to store.What's storage like with this one? Is it easier to manage than the others?
AstraZeneca is having severe production issues.This and the astrazeneca vaccine are going to be key in getting as many people shots as possible
It's likely too late now. I'd think. Already at its YTD high.I debated buying J&J stock looking at Moderna/Pfizer gains post announcement and it looks ... like a reasonable buy?
Anyone have thoughts?
It's an adenovirus vector like Oxford/AZ. Basically those types use a harmless virus humans haven't been exposed to that acts as a trojan horse to train our immune system to what we really want it to fight (the spike protein).
10-14 days